Post-approval studies (Phase 4)Study completedNCT02064816
What this trial is testing
Rebif® in Subjects With Relapsing Multiple Sclerosis
Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 200
Showing 20 of 0 results